BioStack Raises $9.5M Seed to Build Cross-Border Health Data Network

Healthtech startup BioStack has raised $9.5 million in a seed round led by Peak XV, with Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator also participating.

The company said the money will fund expansion across the United States and international markets, development of its technology platform, and growth of its engineering and research teams. What it did not say: how long that capital is expected to last, or whether revenue is yet covering operating costs.

Alongside the raise, BioStack is launching a data infrastructure network spanning the US, India, Brazil and Argentina, with access to over 100 million de-identified patient records. That figure is roughly equivalent to the combined populations of Argentina and Chile — an unusually large corpus for a seed-stage company, though the company did not specify how many of those records are complete versus partial.

What does BioStack actually build?

BioStack creates workflows that bring together clinical information across disparate health systems and geographies. It connects notes, labs, imaging, medications, treatments and outcomes, aiming to give clinicians and researchers a comprehensive view of the patient and to inform population-level and hospital-level discovery.

Sanat Mishra, Co-founder and CEO of BioStack, laid out the thesis: "Collecting every event linked to each patient enables a view of what happens at each stage of a patient's journey."

"We're building the infrastructure that connects all of the clinical information and makes it useful, both for clinicians making decisions today and for the researchers and AI developers building the future of medicine," Mishra said.

The promise is a single thread through fragmented records. The caveat: stitching together data from four countries with different health systems, languages and privacy regimes is an engineering and regulatory challenge the statement leaves unaddressed.

How does the data network work?

The company builds proprietary datasets from de-identified data collected from each provider system. It links biological and clinical data with treatment histories and long-term outcomes, which it says helps researchers understand what happened to a patient and how different interventions affected their health over time.

BioStack frames this as a feedback loop between clinical care and medical innovation. As more longitudinal patient information becomes available, researchers and AI developers can build a richer picture of disease progression and treatment response.

The scale is already substantial. According to the company, it has combined several hundred thousand fragmented X-rays, MRIs and CT scans with over several million telehealth audio transcripts, alongside other pathology and clinical records. The resulting dataset, BioStack said, is a resource for training AI agents that help clinicians evaluate treatment options and likely patient outcomes.

Note the vague quantifiers: "several hundred thousand" and "several million" are company characterizations, not audited figures.

Why four countries matter

BioStack currently works with hospitals across the US, Brazil, India and Argentina. The company says this gives it access to a diverse patient population and healthcare environments — a diversity that matters for training AI tools meant to generalize across demographics rather than one system's patient mix.

Diversity cuts both ways. Data heterogeneity across four markets raises integration costs, and the company disclosed neither the number of hospital partners nor the commercial terms of those relationships.

What comes next?

The seed round buys BioStack runway to scale its network before the hard questions — monetization, regulatory scrutiny of de-identified data, and proof that its datasets meaningfully improve clinical AI — come due. The bet from eight investors, including Y Combinator and Peak XV, is that whoever owns the connective tissue of global clinical data will shape the next era of medicine.